Last updated: April 23, 2026
Who supplies perampanel active pharmaceutical ingredient (API)?
Perampanel is a controlled, specialty antiepileptic API produced through small-molecule chemical synthesis. Market supply is dominated by a handful of API manufacturers and a broader set of contract manufacturers (both in-house and outsourced for finishing), with additional sourcing through regional distributor networks.
Primary API supply channels (practical sourcing view)
- Direct API manufacturers (commercial bulk perampanel API, plus validation/DMF-linked technical packages)
- DMF-holding API suppliers (route-specific synthesis with regulatory documentation support)
- Broker-distributor networks (API procurement via trading houses and regional distributors, often without additional chemistry changes)
API manufacturing reality check
- Perampanel is typically produced as a chemically defined small molecule with defined polymorphic and impurity specs, so buyers usually require:
- CoA with identity and assay by validated methods
- Impurity profile aligned to the applicable regulatory dossier
- Particle size and polymorph confirmation (where relevant to formulation performance)
Which contract manufacturers (CDMO/CMO) finish perampanel drug product (tablets)?
Perampanel is marketed as tablets. Drug product supply therefore runs through CDMOs/CMOs that handle:
- Tablet formulation (blend, granulation, compression or direct compression depending on site method)
- Film coating (where required by the marketed brand)
- Packaging (bottles/blister lines)
- Release and stability (GxP manufacturing records, stability programs)
In practice, “tablet supply” is split across:
- Primary commercial manufacturers (NDA/MAA commercial supply)
- Secondary/backup manufacturers (additional sites for continuity, supply assurance, and capacity)
What raw materials typically determine perampanel sourcing risk?
Perampanel synthesis is sensitive to upstream intermediates and controlling reagents used in key steps. For procurement and vendor qualification, the material risk usually concentrates in:
- Key building blocks and intermediates tied to the specific synthetic route
- Chiral or stereochemically controlled intermediates (if any step uses stereochemical control)
- Controlled reagents or restricted chemicals where regulatory handling can slow supply
- Solvents and drying capacity for purification and isolation steps
These upstream dependencies are where supplier substitutions usually fail first, because analytical comparability depends on impurity carryover and solid-state attributes.
Which suppliers should be screened first for perampanel procurement?
For a procurement and vendor qualification program, the most actionable supplier-screening targets are:
-
API vendors that hold regulatory documentation (DMF/EDMF or equivalent) for perampanel
- Screening criteria: dossier completeness, impurity acceptance ranges, change-control history, and audit results.
-
CDMOs with demonstrated small-molecule solid oral dosage experience
- Screening criteria: tablet line uptime, compression/coating capabilities, and stability capacity for the product’s target shelf life.
-
Multi-site manufacturers with validated second-source capability
- Screening criteria: ability to qualify alternate API without major reformulation, demonstrated comparability packages, and supply continuity plans.
Market structure: how perampanel supply typically routes to brands
Perampanel’s drug product supply chain commonly works as follows:
- API sourced from specialty API manufacturers or DMF-holding vendors
- Drug product manufactured by a CMO/CDMO under commercial supply agreements
- Finished goods distributed via wholesalers/distributors into branded markets
This structure matters because the “supplier list” for perampanel is not a single roster. It is split into API suppliers and tablet manufacturers, then bridged by distribution partners.
Key supplier qualification checklist for perampanel
Any supplier considered for perampanel should meet procurement requirements aligned to solid oral and small-molecule impurity controls:
- Regulatory package alignment
- DMF access for API
- CoA and batch release aligned to dossier specs
- Analytical comparability
- Identity tests (e.g., IR/DSC/HPLC method suite)
- Impurity profile and known related substances control
- Solid-state and formulation-relevant controls
- Polymorph/solid form verification policy
- Moisture and particle size controls (where specified in the formulation development history)
- Quality systems and audit readiness
- GMP compliance and audit history
- Change control maturity for process and raw materials
Key Takeaways
- Perampanel supply is split between API suppliers and tablet CMO/CDMO manufacturers, with distribution bridges into branded markets.
- The most decision-relevant supplier screen focuses on regulatory documentation (DMF/EDMF), impurity/analytical control, and solid-state/formulation comparability.
- Procurement risk is highest at upstream intermediates and controlled reagents, not at generic packaging or non-critical processing steps.
FAQs
-
Is perampanel API supply limited to a few vendors?
Supply concentrates among specialty small-molecule API manufacturers with established regulatory documentation and impurity control systems.
-
What matters most when qualifying a new perampanel API supplier?
The supplier must align to the dossier impurity profile and provide validated analytical support that supports formulation comparability.
-
Do tablet manufacturers matter more than API suppliers for supply continuity?
Both matter; tablet CMO capacity can become the bottleneck even if API supply is available, so dual-site manufacturing capability is a key continuity lever.
-
What are the main reasons perampanel sourcing changes fail?
Impurity drift, uncontrolled solid-state attributes, and inability to demonstrate comparability through required analytical and stability packages.
-
What procurement documents should be requested from perampanel suppliers?
CoA/batch release data, DMF or equivalent regulatory documentation, analytical method summaries, and change-control documentation.
Sources (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMF). FDA. https://www.accessdata.fda.gov/scripts/cder/dmf/
[2] European Medicines Agency. (n.d.). European database of drug master files. EMA. https://www.ema.europa.eu/
[3] FDA. (n.d.). cGMP for Finished Pharmaceuticals (and related guidance). U.S. FDA. https://www.fda.gov/
